Mutant p53 R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells

I. Kogan-Sakin; Y. Tabach; Y. Buganim; A. Molchadsky; H. Solomon; S. Madar; I. Kamer; P. Stambolsky; A. Shelly; N. Goldfinger; S. Valsesia-Wittmann; A. Puisieux; A. Zundelevich; E. N. Gal-Yam; C. Avivi; I. Barshack; M. Brait; D. Sidransky; E. Domany; V. Rotter

doi:10.1038/cdd.2010.94

Mutant p53 R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells

I. Kogan-Sakin, Y. Tabach, Y. Buganim, A. Molchadsky, H. Solomon, S. Madar, I. Kamer, P. Stambolsky, A. Shelly, N. Goldfinger, S. Valsesia-Wittmann, A. Puisieux, A. Zundelevich, E. N. Gal-Yam, C. Avivi, I. Barshack, M. Brait, D. Sidransky, E. Domany, V. Rotter^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

133 Scopus citations

Abstract

A mutation within one allele of the p53 tumor suppressor gene can inactivate the remaining wild-type allele in a dominant-negative manner and in some cases can exert an additional oncogenic activity, known as mutant p53 gain of function (GOF). To study the role of p53 mutations in prostate cancer and to discriminate between the dominant-negative effect and the GOF activity of mutant p53, we measured, using microarrays, the expression profiles of three immortalized prostate epithelial cultures expressing wild-type, inactivated p53 or mutated p53. Analysis of these gene expression profiles showed that both inactivated p53 and p53 R175H mutant expression resulted in the upregulation of cell cycle progression genes. A second group, which was upregulated exclusively by mutant p53 R175H, was predominantly enriched in developmental genes. This group of genes included the Twist1, a regulator of metastasis and epithelial-mesenchymal transition (EMT). Twist1 levels were also elevated in metastatic prostate cancer-derived cell line DU145, in immortalized lung fibroblasts and in a subset of lung cancer samples, all in a mutant p53-dependent manner. p53 R175H mutant bearing immortalized epithelial cells showed typical features of EMT, such as higher expression of mesenchymal markers, lower expression of epithelial markers and enhanced invasive properties in vitro. The mechanism by which p53 R175H mutant induces Twist1 expression involves alleviation of the epigenetic repression. Our data suggest that Twist1 expression might be upregulated following p53 mutation in cancer cells.

Original language	English
Pages (from-to)	271-281
Number of pages	11
Journal	Cell Death and Differentiation
Volume	18
Issue number	2
DOIs	https://doi.org/10.1038/cdd.2010.94
State	Published - Feb 2011
Externally published	Yes

Bibliographical note

Funding Information:
Acknowledgements. This research was supported by a Center of Excellence grant from Flight Attendant Medical Research Institute (FAMRI), EC FP6 Grant LSHC-CT-2004-503576, the Yad Abraham Center for Cancer Diagnosis and Therapy and the Ridgefield Foundation. Partial funding was provided by the Center for Women’s Health Research. This publication reflects the authors’ views and not necessarily those of the European Community. The EC is not liable for any use that may be made of the information contained herein. VR is the incumbent of the Norman and Helen Asher Professorial Chair Cancer Research at the Weizmann institute. ED is the incumbent of the Henry J Leir Professorial Chair. We are grateful to Alla Voldman and Leslie Pomeraniec for technical assistance.

Keywords

Twist1
p53
prostate

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/cdd.2010.94

Cite this

Kogan-Sakin, I., Tabach, Y., Buganim, Y., Molchadsky, A., Solomon, H., Madar, S., Kamer, I., Stambolsky, P., Shelly, A., Goldfinger, N., Valsesia-Wittmann, S., Puisieux, A., Zundelevich, A., Gal-Yam, E. N., Avivi, C., Barshack, I., Brait, M., Sidransky, D., Domany, E., & Rotter, V. (2011). Mutant p53 R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death and Differentiation, 18(2), 271-281. https://doi.org/10.1038/cdd.2010.94

@article{e7f881ab6a954c5e93d04612cd3c370a,

title = "Mutant p53 R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells",

abstract = "A mutation within one allele of the p53 tumor suppressor gene can inactivate the remaining wild-type allele in a dominant-negative manner and in some cases can exert an additional oncogenic activity, known as mutant p53 gain of function (GOF). To study the role of p53 mutations in prostate cancer and to discriminate between the dominant-negative effect and the GOF activity of mutant p53, we measured, using microarrays, the expression profiles of three immortalized prostate epithelial cultures expressing wild-type, inactivated p53 or mutated p53. Analysis of these gene expression profiles showed that both inactivated p53 and p53 R175H mutant expression resulted in the upregulation of cell cycle progression genes. A second group, which was upregulated exclusively by mutant p53 R175H, was predominantly enriched in developmental genes. This group of genes included the Twist1, a regulator of metastasis and epithelial-mesenchymal transition (EMT). Twist1 levels were also elevated in metastatic prostate cancer-derived cell line DU145, in immortalized lung fibroblasts and in a subset of lung cancer samples, all in a mutant p53-dependent manner. p53 R175H mutant bearing immortalized epithelial cells showed typical features of EMT, such as higher expression of mesenchymal markers, lower expression of epithelial markers and enhanced invasive properties in vitro. The mechanism by which p53 R175H mutant induces Twist1 expression involves alleviation of the epigenetic repression. Our data suggest that Twist1 expression might be upregulated following p53 mutation in cancer cells.",

keywords = "Twist1, p53, prostate",

author = "I. Kogan-Sakin and Y. Tabach and Y. Buganim and A. Molchadsky and H. Solomon and S. Madar and I. Kamer and P. Stambolsky and A. Shelly and N. Goldfinger and S. Valsesia-Wittmann and A. Puisieux and A. Zundelevich and Gal-Yam, {E. N.} and C. Avivi and I. Barshack and M. Brait and D. Sidransky and E. Domany and V. Rotter",

note = "Funding Information: Acknowledgements. This research was supported by a Center of Excellence grant from Flight Attendant Medical Research Institute (FAMRI), EC FP6 Grant LSHC-CT-2004-503576, the Yad Abraham Center for Cancer Diagnosis and Therapy and the Ridgefield Foundation. Partial funding was provided by the Center for Women{\textquoteright}s Health Research. This publication reflects the authors{\textquoteright} views and not necessarily those of the European Community. The EC is not liable for any use that may be made of the information contained herein. VR is the incumbent of the Norman and Helen Asher Professorial Chair Cancer Research at the Weizmann institute. ED is the incumbent of the Henry J Leir Professorial Chair. We are grateful to Alla Voldman and Leslie Pomeraniec for technical assistance.",

year = "2011",

month = feb,

doi = "10.1038/cdd.2010.94",

language = "אנגלית",

volume = "18",

pages = "271--281",

journal = "Cell Death and Differentiation",

issn = "1350-9047",

publisher = "Nature Publishing Group",

number = "2",

}

Kogan-Sakin, I, Tabach, Y , Buganim, Y, Molchadsky, A, Solomon, H, Madar, S, Kamer, I, Stambolsky, P, Shelly, A, Goldfinger, N, Valsesia-Wittmann, S, Puisieux, A, Zundelevich, A, Gal-Yam, EN, Avivi, C, Barshack, I, Brait, M, Sidransky, D, Domany, E & Rotter, V 2011, 'Mutant p53 R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells', Cell Death and Differentiation, vol. 18, no. 2, pp. 271-281. https://doi.org/10.1038/cdd.2010.94

TY - JOUR

T1 - Mutant p53 R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells

AU - Kogan-Sakin, I.

AU - Tabach, Y.

AU - Buganim, Y.

AU - Molchadsky, A.

AU - Solomon, H.

AU - Madar, S.

AU - Kamer, I.

AU - Stambolsky, P.

AU - Shelly, A.

AU - Goldfinger, N.

AU - Valsesia-Wittmann, S.

AU - Puisieux, A.

AU - Zundelevich, A.

AU - Gal-Yam, E. N.

AU - Avivi, C.

AU - Barshack, I.

AU - Brait, M.

AU - Sidransky, D.

AU - Domany, E.

AU - Rotter, V.

N1 - Funding Information: Acknowledgements. This research was supported by a Center of Excellence grant from Flight Attendant Medical Research Institute (FAMRI), EC FP6 Grant LSHC-CT-2004-503576, the Yad Abraham Center for Cancer Diagnosis and Therapy and the Ridgefield Foundation. Partial funding was provided by the Center for Women’s Health Research. This publication reflects the authors’ views and not necessarily those of the European Community. The EC is not liable for any use that may be made of the information contained herein. VR is the incumbent of the Norman and Helen Asher Professorial Chair Cancer Research at the Weizmann institute. ED is the incumbent of the Henry J Leir Professorial Chair. We are grateful to Alla Voldman and Leslie Pomeraniec for technical assistance.

PY - 2011/2

Y1 - 2011/2

N2 - A mutation within one allele of the p53 tumor suppressor gene can inactivate the remaining wild-type allele in a dominant-negative manner and in some cases can exert an additional oncogenic activity, known as mutant p53 gain of function (GOF). To study the role of p53 mutations in prostate cancer and to discriminate between the dominant-negative effect and the GOF activity of mutant p53, we measured, using microarrays, the expression profiles of three immortalized prostate epithelial cultures expressing wild-type, inactivated p53 or mutated p53. Analysis of these gene expression profiles showed that both inactivated p53 and p53 R175H mutant expression resulted in the upregulation of cell cycle progression genes. A second group, which was upregulated exclusively by mutant p53 R175H, was predominantly enriched in developmental genes. This group of genes included the Twist1, a regulator of metastasis and epithelial-mesenchymal transition (EMT). Twist1 levels were also elevated in metastatic prostate cancer-derived cell line DU145, in immortalized lung fibroblasts and in a subset of lung cancer samples, all in a mutant p53-dependent manner. p53 R175H mutant bearing immortalized epithelial cells showed typical features of EMT, such as higher expression of mesenchymal markers, lower expression of epithelial markers and enhanced invasive properties in vitro. The mechanism by which p53 R175H mutant induces Twist1 expression involves alleviation of the epigenetic repression. Our data suggest that Twist1 expression might be upregulated following p53 mutation in cancer cells.

AB - A mutation within one allele of the p53 tumor suppressor gene can inactivate the remaining wild-type allele in a dominant-negative manner and in some cases can exert an additional oncogenic activity, known as mutant p53 gain of function (GOF). To study the role of p53 mutations in prostate cancer and to discriminate between the dominant-negative effect and the GOF activity of mutant p53, we measured, using microarrays, the expression profiles of three immortalized prostate epithelial cultures expressing wild-type, inactivated p53 or mutated p53. Analysis of these gene expression profiles showed that both inactivated p53 and p53 R175H mutant expression resulted in the upregulation of cell cycle progression genes. A second group, which was upregulated exclusively by mutant p53 R175H, was predominantly enriched in developmental genes. This group of genes included the Twist1, a regulator of metastasis and epithelial-mesenchymal transition (EMT). Twist1 levels were also elevated in metastatic prostate cancer-derived cell line DU145, in immortalized lung fibroblasts and in a subset of lung cancer samples, all in a mutant p53-dependent manner. p53 R175H mutant bearing immortalized epithelial cells showed typical features of EMT, such as higher expression of mesenchymal markers, lower expression of epithelial markers and enhanced invasive properties in vitro. The mechanism by which p53 R175H mutant induces Twist1 expression involves alleviation of the epigenetic repression. Our data suggest that Twist1 expression might be upregulated following p53 mutation in cancer cells.

KW - Twist1

KW - p53

KW - prostate

UR - http://www.scopus.com/inward/record.url?scp=78651289008&partnerID=8YFLogxK

U2 - 10.1038/cdd.2010.94

DO - 10.1038/cdd.2010.94

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 20689556

AN - SCOPUS:78651289008

SN - 1350-9047

VL - 18

SP - 271

EP - 281

JO - Cell Death and Differentiation

JF - Cell Death and Differentiation

IS - 2

ER -

Mutant p53 R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this